Sandra Le Ngoc Tho1, Florence Ader2, Tristan Ferry2, Daniel Floret3, Maximilien Arnal4, Simone Fargeas5, Christian Chidiac2, Florent Valour6. 1. Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France; Department of General Medicine, Claude Bernard Lyon 1 University, Lyon, France. 2. Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France; INSERM U1111, International Centre for Research in Infectiology, Claude Bernard Lyon 1 University, Lyon, France. 3. Paediatric Department of Emergency and Intensive Care, Hospices Civils de Lyon, Lyon, France; Claude Bernard Lyon 1 University, Lyon, France. 4. Paediatric Orthopaedic Surgery Unit, Hospices Civils de Lyon, Lyon, France. 5. Department of General Medicine, Claude Bernard Lyon 1 University, Lyon, France. 6. Department of Infectious Diseases, Hospices Civils de Lyon, Lyon, France; INSERM U1111, International Centre for Research in Infectiology, Claude Bernard Lyon 1 University, Lyon, France. Electronic address: florent.valour@chu-lyon.fr.
Abstract
BACKGROUND: A vaccine against serogroup B Neisseria meningitidis, major cause of bacterial meningitis in children and adults, has recently been developed. In a context of an increasing parental mistrust against vaccinations, understanding the reason for their choices is crucial in order to improve immunization coverage. Our study aimed at evaluating parental attitudes and perceptions towards serogroup B meningococcal invasive disease vaccination. METHODS: A prospective observational study was conducted in different French independent-practice medical offices (general practitioners and paediatricians) and nurseries between May 1 and December 31, 2013, using a questionnaire distributed in electronic and paper forms to parents having at least one child between the ages of 2 months and 16 years old. RESULTS: 1270 parents were included, of whom 671 (52.8%) spontaneously stated to be in favour of this vaccination. Their choice was mainly justified by the severity of the disease (63.8%) and the desire to protect their child (51.7%). In multivariate analysis, the young age of parents (OR 0.949 per additional year; p<10(-3)), the history of vaccination against serogroup C meningococcal invasive diseases (OR 6.755; p<10(-3)), and the prior knowledge of the vaccine (OR 2.081; p=0.001) were associated with vaccination acceptance. The main reasons for refusal were the lack of hindsight on this new vaccine (50.6%) and the fear of side effects (45.5%). After objective information on the disease and the vaccine, only 6.3% of the entire responding population would refuse to consider vaccination. CONCLUSIONS: The spontaneous acceptance rate of vaccination against serogroup B meningococcal invasive disease is insufficient. However, after objective information by their physician or public health authorities, only a few parents would in the end be completely resistant.
BACKGROUND: A vaccine against serogroup B Neisseria meningitidis, major cause of bacterial meningitis in children and adults, has recently been developed. In a context of an increasing parental mistrust against vaccinations, understanding the reason for their choices is crucial in order to improve immunization coverage. Our study aimed at evaluating parental attitudes and perceptions towards serogroup B meningococcal invasive disease vaccination. METHODS: A prospective observational study was conducted in different French independent-practice medical offices (general practitioners and paediatricians) and nurseries between May 1 and December 31, 2013, using a questionnaire distributed in electronic and paper forms to parents having at least one child between the ages of 2 months and 16 years old. RESULTS: 1270 parents were included, of whom 671 (52.8%) spontaneously stated to be in favour of this vaccination. Their choice was mainly justified by the severity of the disease (63.8%) and the desire to protect their child (51.7%). In multivariate analysis, the young age of parents (OR 0.949 per additional year; p<10(-3)), the history of vaccination against serogroup C meningococcal invasive diseases (OR 6.755; p<10(-3)), and the prior knowledge of the vaccine (OR 2.081; p=0.001) were associated with vaccination acceptance. The main reasons for refusal were the lack of hindsight on this new vaccine (50.6%) and the fear of side effects (45.5%). After objective information on the disease and the vaccine, only 6.3% of the entire responding population would refuse to consider vaccination. CONCLUSIONS: The spontaneous acceptance rate of vaccination against serogroup B meningococcal invasive disease is insufficient. However, after objective information by their physician or public health authorities, only a few parents would in the end be completely resistant.
Authors: Marion de Vries; Liesbeth Claassen; Margreet J M Te Wierik; Danielle R M Timmermans; Aura Timen Journal: BMC Public Health Date: 2022-04-01 Impact factor: 3.295
Authors: Marion de Vries; Liesbeth Claassen; Margreet J M Te Wierik; Feray Coban; Albert Wong; Danielle R M Timmermans; Aura Timen Journal: Emerg Infect Dis Date: 2020-07 Impact factor: 6.883
Authors: Marzena Drozd-Dąbrowska; Katarzyna Topczewska; Marcin Korzeń; Anna Sałacka; Maria Ganczak Journal: Int J Environ Res Public Health Date: 2019-01-18 Impact factor: 3.390